These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 12692572)

  • 1. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H; Hayashi K; Saruta T
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease.
    Matsuda H; Hayashi K; Homma K; Yoshioka K; Kanda T; Takamatsu I; Tatematsu S; Wakino S; Saruta T
    Hypertens Res; 2003 Nov; 26(11):875-80. PubMed ID: 14714578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease.
    Weinberg AJ; Zappe DH; Ramadugu R; Weinberg MS
    J Hypertens Suppl; 2006 Mar; 24(1):S95-9. PubMed ID: 16601581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy].
    Kuriyama S; Tomonari H; Ohtsuka Y; Ohkido I; Hosoya T
    Nihon Jinzo Gakkai Shi; 2003; 45(4):367-71. PubMed ID: 12806973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
    Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
    Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.
    Kohzuki M; Kanazawa M; Liu PF; Kamimoto M; Yoshida K; Saito T; Yasujima M; Sato T; Abe K
    J Hypertens; 1995 Dec; 13(12 Pt 2):1785-90. PubMed ID: 8903652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
    Renke M; Rutkowski P; Tylicki L; Zietkiewicz M; Larczyński W; Rutkowski B
    Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G
    Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels.
    Komine N; Khang S; Wead LM; Blantz RC; Gabbai FB
    Am J Kidney Dis; 2002 Jan; 39(1):159-64. PubMed ID: 11774115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis].
    Kutyrina IM; Tareeva IE; Nosikov VV; Kamyshova ES; Gorashko NM; Chistiakov DA; Okonova EB; Troepol'skaia OV
    Ter Arkh; 1999; 71(6):30-4. PubMed ID: 10420452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y; Taura K; Taguchi T; Furusu A; Kohno S
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.
    Seeman T; Dusek J; Vondrák K; Flögelová H; Geier P; Janda J
    Am J Hypertens; 2004 May; 17(5 Pt 1):415-20. PubMed ID: 15110900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.